trending Market Intelligence /marketintelligence/en/news-insights/trending/47oZk5TlGlfu3C-_bO4LHg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Aeglea BioTherapeutics prices $12.3M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aeglea BioTherapeutics prices $12.3M common stock offering

Aeglea BioTherapeutics Inc. priced an underwritten public offering of 3 million shares at $4.10 apiece to raise $12.3 million in gross proceeds.

The offering is expected to close June 9 with JonesTrading Institutional Services LLC acting as the sole book runner. The underwriter has an option to purchase up to an additional 450,000 of the shares offered.

Aeglea plans to use the net proceeds to fund its research and development product candidates and for other general corporate purposes.